Biosight Initiates First Patient Enrollment in the P-I/II Study of Aspacytarabine + Venetoclax in Acute Myeloid Leukemia


The study is designed to evaluate the safety and efficacy of aspacytarabine + venetoclax for induction therapy of newly-diagnosed AML who are unfit for standard induction CT due to age or comorbidities, followed by aspacytarabine single-agent consolidation therapy at the US
Results from the P-IIb study of aspacytarabine as a single-agent showed safety in 1L AML therapy. Additional studies are ongoing to evaluate aspacytarabine as a 2L treatment for patients with r/r MDS or AML
Aspacytarabine (BST-236) is a novel proprietary anti-metabolite that acts as a cytarabine’s prodrug. The drug has received FTD for 1L treatment of AML and ODD for AML as well as MDS from the US FDA while it also received ODD from the EMA

Ref: PRNewswire | Image: Biosight